The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).
 
Jesus G. Berdeja
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); MEI Pharma (Inst); Onyx (Inst); Takeda (Inst)
 
Tara K. Gregory
Honoraria - Novartis
 
Jeffrey Matous
Consulting or Advisory Role - Celgene; Millennium
Speakers' Bureau - Celgene; Millennium; Onyx; Seagen
Research Funding - Celgene (Inst)
 
Lowell L. Hart
Speakers' Bureau - Onyx
Research Funding - Onyx (Inst)
 
Rami Owera
No Relationships to Disclose
 
Joseph Ronald Mace
No Relationships to Disclose
 
James H. Essell
No Relationships to Disclose
 
Ian Flinn
Research Funding - Novartis (Inst)
 
Edward Anthony Faber
Honoraria - Onyx
Consulting or Advisory Role - Onyx